The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.
The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.
The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.
Single-cell RNA sequencing on thousands of tumor and surrounding cells from 19 melanoma samples revealed subsets of cells with apparent resistance potential.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
The partners will couple Claremont BioSolutions' enzyme-free tissue homogenization technology with IncellDx's reagents.
IncellDx said this week that it has hired Christine Meda as chief business officer.
Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner.
NEW YORK (GenomeWeb News) – IncellDx and Bristol-Myers Squibb have signed an agreement to develop a molecular test that may eventually be used as a companion diagnostic to identify best responders to an investigational drug in BMS's pipeline.
NEW YORK (GenomeWeb News) – IncellDx today said it has reached a deal to offer its molecular diagnostic test for human papillomavirus in India.
Using DNA to sketch crime victims might not be a great idea, the NYTimes says.
Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.
Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.
In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.